Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) is expected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA traded down $0.24 during trading on Tuesday, hitting $14.39. 382,120 shares of the company’s stock traded hands, compared to its average volume of 1,448,195. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -7.74 and a beta of 2.05. Olema Pharmaceuticals has a 12-month low of $3.89 and a 12-month high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.95 and a current ratio of 9.95. The business has a 50 day moving average of $17.14 and a 200-day moving average of $20.16.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on OLMA shares. HC Wainwright lowered their price target on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Wall Street Zen raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. Oppenheimer reissued an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Finally, JPMorgan Chase & Co. increased their price target on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 18th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.40.

Insider Activity

In other news, insider Shawnte Mitchell sold 25,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 16.36% of the company’s stock.

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Zacks Investment Management raised its stake in Olema Pharmaceuticals by 138.0% in the third quarter. Zacks Investment Management now owns 30,803 shares of the company’s stock valued at $302,000 after purchasing an additional 17,863 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Olema Pharmaceuticals in the third quarter valued at approximately $268,000. Cetera Investment Advisers purchased a new stake in Olema Pharmaceuticals in the fourth quarter valued at approximately $262,000. Wealthspire Advisors LLC purchased a new stake in Olema Pharmaceuticals in the fourth quarter valued at approximately $254,000. Finally, EP Wealth Advisors LLC purchased a new stake in Olema Pharmaceuticals in the fourth quarter valued at approximately $250,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.